US Stock MarketDetailed Quotes

AMLX Amylyx Pharmaceuticals

Watchlist

1.740
-0.140-7.45%

Close Jul 2 16:00 ET

1.750
+0.010+0.57%

Post 19:51 ET

118.33MMarket Cap-1626P/E (TTM)

Amylyx Pharmaceuticals Stock Forum

70205719

Jun 22 11:33

$Amylyx Pharmaceuticals(AMLX.US)$ only one pipeline, but failed. game over.

Amar Amin

Jun 21 09:10

$Amylyx Pharmaceuticals(AMLX.US)$ this is it. wake up you lazy dragon 🤣

Amar Amin

Apr 26 18:58

$Amylyx Pharmaceuticals(AMLX.US)$ flat and searching for the new low. How much lower can it be 😂

Rooster77

Apr 16 12:13

$Amylyx Pharmaceuticals(AMLX.US)$ flat

Trytosaveabit

Apr 10 08:07

Update

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...

Jaguar8

Apr 10 08:02

$Amylyx Pharmaceuticals(AMLX.US)$
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...

Moomoo AI

Apr 6 09:07

Analysts predict a revenue drop and higher losses per share for Amylyx Pharmaceuticals, indicating slower sales growth than the market, potentially causing market wariness.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are More Bearish Than They Used To Be

Trytosaveabit

Apr 4 06:20

But some good now! Hehehe

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals To Advance AMX0035 In Wolfram Syndrome And Progressive Supranuclear Palsy, And AMX0114 In Amyotrophic Lateral Sclerosis, Interim Data From Phase 2 Helios Trial Of AMX0035 For Wolfram Syndrome Are Expected In April 2024

Trytosaveabit

Apr 4 06:18

A bit more

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Will Reduce Its Workforce By Approximately 70% To Focus Resources On Key Clinical And Preclinical Programs And Extends Expected Cash Runway Into 2026

Trytosaveabit

Apr 4 06:18

Update! Hmm? Grrr!

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Announces Formal Intention to Remove Relyvrio/Albrioza From The Market
Moomoo 24/7· 1 min ago
Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program; PHOENIX Open Label Extension is ongoing

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall